<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29617507</article-id><article-id pub-id-type="pmc">5873783</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0020</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Closure of Patent Foramen Ovale <italic>versus</italic> Medical
Therapy after Cryptogenic Stroke: Meta-Analysis of Five Randomized Controlled
Trials with 3440 Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>S&#x000e1;</surname><given-names>Michel Pompeu Barros Oliveira</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="c1"/><role>MD, MSc, PhD</role></contrib><contrib contrib-type="author"><name><surname>de Oliveira Neto</surname><given-names>Luiz de Albuquerque Pereira</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>do Nascimento</surname><given-names>Gabriella Caroline Sales</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Vieira</surname><given-names>Erik Everton da Silva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Martins</surname><given-names>Gabriel Lopes</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Rodrigues</surname><given-names>Karine Coelho</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Nascimento</surname><given-names>Giulia Cioffi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>de Menezes</surname><given-names>Alexandre Motta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Lins</surname><given-names>Ricardo Felipe de Albuquerque</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Frederico Pires Vasconcelos</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Ricardo Carvalho</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><role>MD, MSc, PhD, ChM</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Division of Cardiovascular Surgery, Pronto-Socorro
Cardiol&#x000f3;gico de Pernambuco (PROCAPE), Recife, PE, Brazil. </aff><aff id="aff2">
<label>2</label> Universidade de Pernambuco (UPE), Recife, PE, Brazil. </aff><aff id="aff3">
<label>3</label> Nucleus of Postgraduate and Research in Health Sciences of
Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas and Instituto de Ci&#x000ea;ncias
Biol&#x000f3;gicas (FCM/ICB), Recife, PE, Brazil. </aff><aff id="aff4">
<label>4</label> The CASUAL Investigators - CArdiovascular SUgery Academic League of
the Universidade de Pernambuco (UPE), Recife, PE, Brazil. </aff><author-notes><corresp id="c1">Correspondence Address: Michel Pompeu Barros Oliveira S&#x000e1;,
Pronto-Socorro Cardiol&#x000f3;gico de Pernambuco (PROCAPE), Rua dos Palmares S/N
- Santo Amaro - Recife, PE, Brazil - Zip code: 74970-240. E-mail:
<email>michel_pompeu@yahoo.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>33</volume><issue>1</issue><fpage>89</fpage><lpage>98</lpage><history><date date-type="received"><day>19</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>We aimed to determine whether patent foramen ovale closure reduces the risk
of stroke, also assessing some safety outcomes.</p></sec><sec><title>Introduction</title><p>The clinical benefit of closing a patent foramen ovale after a cryptogenic
stroke has been an open question for several decades, so that it is
necessary to review the current state of published medical data in this
regard.</p></sec><sec><title>Methods</title><p>MEDLINE, EMBASE, CENTRAL/CCTR, SciELO, LI-LACS, Google Scholar and reference
lists of relevant articles were searched for randomized controlled trials
that reported any of the following outcomes: stroke, death, major bleeding
or atrial fibrillation. Five studies fulfilled our eligibility criteria and
included 3440 patients (1829 for patent foramen ovale closure and 1611 for
medical therapy).</p></sec><sec><title>Results</title><p>The risk ratio (RR) for stroke in the "device closure" group compared with
the "medical therapy" showed a statistically significant difference between
the groups, favouring the "device closure" group (RR 0.400; 95% CI
0.183-0.873, <italic>P</italic>=0.021). There was no statistically
significant difference between the groups regarding the safety outcomes
death and major bleeding, but we observed an increase in the risk of atrial
fibrillation in the "device closure group (RR 4.000; 95% CI 2.262-7.092,
<italic>P</italic>&#x0003c;0.001). We also observed that the larger the
proportion of effective closure, the lower the risk of stroke.</p></sec><sec><title>Conclusion</title><p>This meta-analysis found that stroke rates are lower with percutaneously
implanted device closure than with medical therapy alone, being these rates
modulated by the rates of effective closure.</p></sec></abstract><kwd-group><kwd>Foramen Ovale, Patent</kwd><kwd>Vascular Closure Devices</kwd><kwd>Meta-Analysis</kwd></kwd-group></article-meta></front><body><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="43%" span="1"/><col width="3%" span="1"/><col width="5%" span="1"/><col width="43%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= American Heart
Association</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PRISMA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Preferred Reporting
Items for Systematic Reviews and Meta-Analyses</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ASA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= American Stroke
Association</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RCTs</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Randomized controlled
trials</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Risk ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LILACS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Literatura
Latino-Americana em Ci&#x000ea;ncias da Sa&#x000fa;de</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SciELO</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Scientific Electronic
Library Online</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MeSH</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Medical Subject
Headings</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard error</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PFO</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Patent foramen
ovale</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PICOS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Population,
Intervention, Comparison, Outcome andStudy design</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><sec><title>Rationale</title><p>The clinical benefit of closing a patent foramen ovale (PFO) after a cryptogenic
stroke has been an open question for several decades. Current American Heart
Association (AHA)/American Stroke Association (ASA) guidelines do not support
the use of PFO closure among patients with PFO and cryptogenic
stroke<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Nevertheless, new randomized controlled trials (RCTs)
were published recently, so that controversy still exists over the preferred
management strategy for patients with cryptogenic stroke and PFO. Therefore, it
is necessary to review the current state of published medical data in this
regard.</p></sec><sec><title>Objective</title><p>We aimed to determine whether PFO closure reduces the risk of stroke, also
assessing some safety outcomes. This analysis was planned in accordance with
current guidelines for performing comprehensive systematic reviews and
meta-analysis with meta-regression, including the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup> guidelines for RCTs. We prespecified our
analytical plan and registered the study protocol with PROSPERO, the
international prospective register of systematic reviews (CRD42018084583).</p></sec></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Eligibility Criteria</title><p>With the PICOS (Population, Intervention, Comparison, Outcome and Study design)
strategy, studies were considered if: 1) the population comprised patients with
recent stroke or transient ischemic attack who had a PFO; 2) there was an
intervention group of device closure; 3) there was a control group receiving
medical therapy; 4) outcomes studied included any of the following: stroke,
death, major bleeding, atrial fibrillation; 5) studies were RCTs.</p></sec><sec><title>Information Sources</title><p>The following databases were used (until December 2017): MEDLINE; EMBASE;
CENTRAL/CCTR (Cochrane Controlled Trials Register); ClinicalTrials.gov;
Scientific Electronic Library Online (SciELO); LILACS (Literatura
Latino-Americana em Ci&#x000ea;ncias da Sa&#x000fa;de); Google Scholar; and
reference lists of relevant articles.</p></sec><sec><title>Search</title><p>We conducted the search with Medical Subject Headings (MeSH) terms ('Foramen
Ovale, Patent' OR 'Patent Oval Foramen ' OR 'Oval Foramen, Patent' OR 'Patent
Foramen Ovale') AND ('Stroke' OR 'Cerebrovascular Accident' OR 'Cerebrovascular
Accidents' OR 'CVA' OR 'CVAs' OR 'Cerebrovascular Apoplexy' OR 'Apoplexy,
Cerebrovascular' OR 'Vascular Accident, Brain' OR 'Brain Vascular Accident ' OR
'Brain Vascular Accidents' OR 'Vascular Accidents, Brain' OR 'Cerebrovascular
Stroke' OR 'Cerebrovascular Strokes' OR 'Stroke, Cerebrovascular' OR 'Strokes,
Cerebrovascular' OR 'Apoplexy' OR 'Cerebral Stroke' OR 'Cerebral Strokes' OR
'Stroke, Cerebral' OR 'Strokes, Cerebral' OR 'Stroke, Acute' OR 'Acute Stroke'
OR 'Acute Strokes' OR 'Strokes, Acute' OR 'Cerebrovascular Accident, Acute' OR
'Acute Cerebrovascular Accident' OR 'Acute Cerebrovascular Accidents' OR
'Cerebrovascular Accidents, Acute').</p></sec><sec><title>Study Selection</title><p>The following steps were taken: 1) identification of titles of records through
databases searching; 2) removal of duplicates; 3) screening and selection of
abstracts; 4) assessment for eligibility through full-text articles; and 5)
final inclusion in study. One reviewer followed steps 1 to 3. Two independent
reviewers followed step 4 and selected studies. Inclusion or exclusion of
studies was decided unanimously. When there was disagreement, a third reviewer
made the final decision.</p></sec><sec><title>Data Items</title><p>The crude endpoints were stroke, death (any cause), major bleeding and atrial
fibrillation.</p></sec><sec><title>Data Collection Process</title><p>Two independent reviewers extracted the data. When there was disagreement about
data, a third reviewer checked the data and made the final decision. From each
study, we extracted patient characteristics, study design, and outcomes.</p></sec><sec><title>Risk of Bias in Individual Studies</title><p>Included studies were assessed for the following characteristics: sequence
generation (randomization); allocation concealment (selection bias); blinding of
participants and personnel (performance bias); blinding of outcome assessors
(detection bias); incomplete outcome data addressed (attrition bias) and
selective outcome reporting (reporting bias). Considering these characteristics,
the papers were classified into A (low risk of bias), B (moderate risk of bias)
or C (high risk of bias). Two independent reviewers assessed risk of bias.
Agreement between the two reviewers was assessed with kappa statistics for
full-text screening and rating of relevance and risk of bias. When there was
disagreement about risk of bias, a third reviewer checked the data and made the
final decision.</p></sec><sec><title>Summary Measures</title><p>The principal summary measures were risk ratio (RR) with 95% CI and
<italic>P</italic> values (considered statistically significant when
<italic>P</italic>&#x0003c;0.05) for stroke, death, major bleeding and atrial
fibrillation. The metaanalysis was completed with the software Comprehensive
Meta-Analysis (version 2, Biostat, Inc., Englewood, NJ, USA).</p></sec><sec><title>Synthesis of Results</title><p>Forest plots were generated for graphical presentations of clinical outcomes, and
we performed the I<sup>2</sup> test and &#x003c7;<sup>2</sup> test for the
assessment of heterogeneity across the studies<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Inter-study heterogeneity was explored
using the &#x003c7;<sup>2</sup> statistic, but the I<sup>2</sup>-value was
calculated to quantify the degree of heterogeneity across the studies that could
not be attributable to chance alone. When I<sup>2</sup> was more than 50%,
significant statistical heterogeneity was considered to be present. Each study
was summarized by the difference in means or RR, depending on the outcome
analyzed. The RR and differences in means were combined across studies using a
weighted DerSimonian-Laird random effects model<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p></sec><sec><title>Risk of Bias Across Studies</title><p>To assess publication bias, a funnel plot was generated for each outcome,
statistically assessed by Begg and Mazumdar's test<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> and Egger's
test<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p></sec><sec><title>Sensitivity Analysis</title><p>Sensitivity analyses included the investigation of the influence of a single
study on the overall effect - by sequentially removing one study - in order to
test the robustness of the main results, so that we could verify whether any
study had an excessive influence on the overall results. Moreover, we also
analyzed the pool data regarding the outcome "stroke" according to the presence
(or absence) of atrial septal aneurysm (hypermobile septum, defined as a septum
primum excursion greater than 10 mm).</p></sec><sec><title>Meta-Regression Analysis</title><p>Meta-regression analyses were performed to determine whether the effects of the
PFO closure were modulated by prespecified factors. Meta-regression graphs
describe the effect of aspirin on the outcome (plotted on the y-axis) as a
function of a given factor (plotted as a mean or proportion of that factor on
the x-axis). Meta-regression coefficients show the estimated increase in log RR
per unit increase in the covariate. Since log RR &#x0003e; 0 corresponds to RR &#x0003e; 1
and log RR &#x0003c; 0 corresponds to RR &#x0003c; 1, a negative coefficient would
indicate that as a given factor increases, the RR decreases, and vice versa.</p><p>The predetermined modulating factors to be examined were: age (mean - years),
male gender (%), hypertension (%), smoking (%), large shunt before the
interventions, atrial septal aneurysm and effective closure (freedom from large
shunt after the interventions).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Study Selection</title><p>A total of 3,740 citations were identified, of which 9 studies were potentially
relevant and retrieved as full-text. Five<sup>[<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r11" ref-type="bibr">11</xref>]</sup> publications fulfilled our eligibility criteria.
Interobserver reliability of study relevance was excellent (Kappa = 0.81).
Agreement for decisions related to study validity was very good (Kappa = 0.83).
The search strategy can be seen in <xref ref-type="fig" rid="f1">Figure
1</xref>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flow diagram of studies included in data search.</p><p>CENTRAL/CCTR=Cochrane Central Register of Controlled Trials;
LILACS=Latin American and Caribbean Health Sciences Literature;
SciELO=Scientific Electronic Library Online</p></caption><graphic xlink:href="rbccv-33-01-0089-g01"/></fig>
</p></sec><sec><title>Study Characteristics</title><p>A total of 3,440 patients (device closure: 1,829 patients; medical therapy: 1,611
patients) were included from studies published from 2012 to 2017. All the trials
were multicentric. Most studies consisted of patients whose mean or median age
was approximately the fourth decade of life. The medical therapy in the studies
was not homogeneous, since different regimens were applied (aspirin,
clopidogrel, dipyridamole, combined regimens, etc.). The same goes for the
devices used, being the CLOSE trial<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> noteworthy for applying various devices (see
<xref ref-type="table" rid="t1">Table 1</xref>). The overall internal
validity was considered "low risk of bias" (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of the populations.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">CLOSE &#x000a0;(N=473)</th><th align="center" rowspan="1" colspan="1">REDUCE (N=664)</th><th align="center" rowspan="1" colspan="1">PC&#x000a0;(N=414)</th><th align="center" rowspan="1" colspan="1">RESPECT (N=980)</th><th align="center" rowspan="1" colspan="1">CLOSURE (N=909)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">% of data in metanalysis</td><td align="center" rowspan="1" colspan="1">13.7</td><td align="center" rowspan="1" colspan="1">19.3</td><td align="center" rowspan="1" colspan="1">12.0</td><td align="center" rowspan="1" colspan="1">28.4</td><td align="center" rowspan="1" colspan="1">26.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Demographic variables</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Age &#x000b1; SD,
years</td><td align="center" rowspan="1" colspan="1">43.3&#x000b1;10.3</td><td align="center" rowspan="1" colspan="1">45.1&#x000b1;9.45</td><td align="center" rowspan="1" colspan="1">44.5&#x000b1;10.2</td><td align="center" rowspan="1" colspan="1">45.4&#x000b1;9.8</td><td align="center" rowspan="1" colspan="1">45.5&#x000b1;10.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male (%)</td><td align="center" rowspan="1" colspan="1">58.9</td><td align="center" rowspan="1" colspan="1">60.1</td><td align="center" rowspan="1" colspan="1">49.8</td><td align="center" rowspan="1" colspan="1">54.7</td><td align="center" rowspan="1" colspan="1">51.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Medical history variables</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Current smoking
(%)</td><td align="center" rowspan="1" colspan="1">28.9</td><td align="center" rowspan="1" colspan="1">13.3</td><td align="center" rowspan="1" colspan="1">23.9</td><td align="center" rowspan="1" colspan="1">13.3</td><td align="center" rowspan="1" colspan="1">15.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Coronary artery
disease (%)</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">2.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Diabetes (%)</td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="1" colspan="1">4.2</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">7.4</td><td align="center" rowspan="1" colspan="1">7.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hyphercholesterolemia (%)</td><td align="center" rowspan="1" colspan="1">13.9</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">27.1</td><td align="center" rowspan="1" colspan="1">39.5</td><td align="center" rowspan="1" colspan="1">44.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hypertension
(%)</td><td align="center" rowspan="1" colspan="1">10.7</td><td align="center" rowspan="1" colspan="1">25.6</td><td align="center" rowspan="1" colspan="1">25.8</td><td align="center" rowspan="1" colspan="1">31.4</td><td align="center" rowspan="1" colspan="1">31.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Migraine (%)</td><td align="center" rowspan="1" colspan="1">30.6</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">20.5</td><td align="center" rowspan="1" colspan="1">38.8</td><td align="center" rowspan="1" colspan="1">33.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Prior stroke/TIA
(%)</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">37.4</td><td align="center" rowspan="1" colspan="1">18.6</td><td align="center" rowspan="1" colspan="1">12.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Echocardiographic variables</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Atrial septal
aneurysm (%)</td><td align="center" rowspan="1" colspan="1">32.7</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">23.7</td><td align="center" rowspan="1" colspan="1">35.6</td><td align="center" rowspan="1" colspan="1">35.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Large shunt
(%)</td><td align="center" rowspan="1" colspan="1">92.8</td><td align="center" rowspan="1" colspan="1">39.3</td><td align="center" rowspan="1" colspan="1">21.7</td><td align="center" rowspan="1" colspan="1">76.1</td><td align="center" rowspan="1" colspan="1">61.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment variables</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Randomized to
device closure (%)</td><td align="center" rowspan="1" colspan="1">50.3</td><td align="center" rowspan="1" colspan="1">66.4</td><td align="center" rowspan="1" colspan="1">49.3</td><td align="center" rowspan="1" colspan="1">50.9</td><td align="center" rowspan="1" colspan="1">49.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Treated with
antiplatelets only (%)</td><td align="center" rowspan="1" colspan="1">49.6</td><td align="center" rowspan="1" colspan="1">33.6</td><td align="center" rowspan="1" colspan="1">80.0</td><td align="center" rowspan="1" colspan="1">88.0</td><td align="center" rowspan="1" colspan="1">84.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Device</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Amplatzer PFO Occluder or Cribriform; Starflex;
CardioSeal; Intrasept PFO; PFOStar; Helex; Premere; PFO occluder
OCCLUTECH; PFO occluder GORE (GSO)</td><td align="center" rowspan="1" colspan="1">EITHER the Helex Septal Occluder device OR the
Cardioform Septal Occluder</td><td align="center" rowspan="1" colspan="1">Amplatzer PFO Occluder (St. Jude Medical)</td><td align="center" rowspan="1" colspan="1">Amplatzer PFO Occluder (disc occluder)</td><td align="center" rowspan="1" colspan="1">STARFlex septal closure system (umbrella
occluder)</td></tr></tbody></table></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Analysis of risk of bias: internal validity.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Randomization</th><th align="center" rowspan="1" colspan="1">Selection bias</th><th align="center" rowspan="1" colspan="1">Performance bias</th><th align="center" rowspan="1" colspan="1">Detection bias</th><th align="center" rowspan="1" colspan="1">Attrition bias</th><th align="center" rowspan="1" colspan="1">Reporting bias</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CLOSE 2017</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">REDUCE 2017</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">RESPECT 2013</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">PC 2013</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">CLOSURE I 2012</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>A=risk of bias is low; B=risk of bias is moderate; C=risk of bias is
high; D=incomplete reporting</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Synthesis of Results</title><p>The RR for stroke in the "device closure" group compared with the "medical
therapy" group in each study is reported in <xref ref-type="fig" rid="f2">Figure
2</xref>. There was evidence of moderate heterogeneity of treatment effect
among the studies for stroke. The overall RR (95% CI) of stroke showed a
statistically significant difference between the groups, favouring the "device
closure" group (random effect model: RR 0.400; 95% CI 0.183-0.873,
<italic>P</italic>=0.021).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Forest plots of efficacy outcomes.</p></caption><graphic xlink:href="rbccv-33-01-0089-g02"/></fig>
</p><p>The RR for death in the "device closure" group compared with the "medical
therapy" group in each study is reported in <xref ref-type="fig" rid="f3">Figure
3A</xref>. There was no evidence of heterogeneity of treatment effect among
the studies for death. The overall RR (95% CI) of death showed no statistically
significant difference between the groups (random effect model: RR 0.760; 95% CI
0.308-1.877, <italic>P</italic>=0.552).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Forest plots of safety outcomes.</p></caption><graphic xlink:href="rbccv-33-01-0089-g03"/></fig>
</p><p>The RR for major bleeding in the "device closure" group compared with the
"medical therapy" group in each study is reported in <xref ref-type="fig" rid="f3">Figure 3B</xref>. There was evidence of mild heterogeneity of
treatment effect among the studies for major bleeding. The overall RR (95% CI)
of major bleeding showed no statistically significant difference between the
groups (random effect model: RR 0.945; 95% CI 0.468-0.873,
<italic>P</italic>=1.911).</p><p>The RR for atrial fibrillation in the "device closure" group compared with the
"medical therapy" group in each study is reported in <xref ref-type="fig" rid="f3">Figure 3C</xref>. There was evidence of mild heterogeneity of
treatment effect among the studies for atrial fibrillation. The overall RR (95%
CI) of atrial fibrillation showed a statistically significant difference between
the groups (random effect model: RR 4.000; 95% CI 2.262-7.092,
<italic>P</italic>&#x0003c;0.001).</p></sec><sec><title>Risk of Bias Across Studies</title><p>Funnel plot analysis (<xref ref-type="fig" rid="f4">Figure 4</xref>) disclosed no
asymmetry around the axis for the outcomes stroke, major bleeding and atrial
fibrillation, which means that we have low risk of publication bias related to
these outcomes. However, we detected a possibility of publication bias for the
outcome death.</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Publication bias analysis of clinical outcomes by funnel plot
graphic.</p></caption><graphic xlink:href="rbccv-33-01-0089-g04"/></fig>
</p></sec><sec><title>Sensitivity Analysis</title><p>Sensitivity analyses performed by removing each single study from the
meta-analysis to determine the influence of individual data sets to the pooled
RR, showed that none of the studies had a particular impact on the results
(<xref ref-type="fig" rid="f5">Figure 5</xref>).</p><p>
<fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Sensitivity analysis - one study removed.</p></caption><graphic xlink:href="rbccv-33-01-0089-g05"/></fig>
</p><p>Searching for evidence of a particular impact of the presence of an atrial septal
aneurysm on the results, we detected no difference between the groups (<xref ref-type="fig" rid="f6">Figure 6</xref>). Unfortunately, the REDUCE
trial<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>
was left out of this last analysis because the presence of an atrial septal
aneurysm was determined at the time of the PFO closure procedure and, therefore,
it was not recorded before trial entry or among the patients in the
antiplatelet-only group.</p><p>
<fig id="f6" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Sensitivity analysis for the presence of an atrial septal
aneurysm.</p></caption><graphic xlink:href="rbccv-33-01-0089-g06"/></fig>
</p></sec><sec><title>Meta-Regression Analysis</title><p>Meta-regression coefficients were statistically significant for, age,
hypertension, atrial septal aneurysm and effective closure regarding the outcome
"stroke". For the variables age, hypertension and atrial septal aneurysm, we
observed that the older the patients, the larger the proportion of patients with
hypertension and the larger the proportion of patients with atrial septal
aneurysm, the higher the risk of stroke (<xref ref-type="fig" rid="f7">Figures
7A</xref>, <xref ref-type="fig" rid="f7">7B</xref>, <xref ref-type="fig" rid="f7">7C</xref>). Conversely, the larger the proportion of effective
closure, the lower the risk of stroke (<xref ref-type="fig" rid="f7">Figure
7D</xref>).</p><p>
<fig id="f7" orientation="portrait" position="float"><label>Fig. 7</label><caption><p>Meta-regression analysis.</p></caption><graphic xlink:href="rbccv-33-01-0089-g07"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><sec><title>Summary of Evidence</title><p>To our knowledge, this is the largest meta-analysis of studies performed to date
that provides incremental value by demonstrating that patients seem to benefit
from device closures in comparison to medical therapy in the reduction of the
rate of stroke. On the other hand, there was an increase in the rates of atrial
fibrillation. We did not identify the group of patients with an atrial septal
aneurysm as a particular group that benefits from the device closure in the
sensitivity analysis, although we identified this variable as a risk marker for
stroke in the meta-regression. We also observed that the benefit of the device
closure in the reduction of the rates of stroke hinges on the rate of effective
closure.</p></sec><sec><title>Some Considerations</title><p>About 25% of the population has a PFO, but the condition in itself does not
increase the risk of ischemic stroke<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. PFO is more prevalent, however, among patients
who had a cryptogenic ischemic stroke than in the general
population<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Therefore, we must be careful when selecting
patients who would receive some benefit of PFO closure (in term of the risk of
stroke).</p><p>Kent et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>
carried out a patient-level analysis of the CLOSURE I<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>, PC<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> and
RESPECT<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> trials (before the publication of the
CLOSE<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>
and REDUCE<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>
trials), demonstrating that the device closure was superior to medical therapy,
which turned out to be confirmed in our meta-analysis (in terms of the outcome
stroke). The improved efficacy in the CLOSE<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> and REDUCE<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> trials might be owing to
more strict patient selection. The REDUCE<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> trial had a very strict criteria to
exclude patients with other sources of stroke and the CLOSE<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> trial only included
those with an atrial septal aneurysm or large shunt.</p></sec><sec><title>The Role of Atrial Septal Aneurysm</title><p>Our results do not suggest that this purportedly high-risk anatomical feature is,
by itself, very useful at discriminating patients likely to benefit from closure
from those unlikely to benefit. Nevertheless, von Klemperer et
al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>,
in a survey of current practice in the United Kingdom, identified that around
80% of the 120 respondents (including cardiologists, stroke physicians and
neurologists) agreed that an aneurysmal septum was more likely to implicate the
PFO in stroke. Only the CLOSE<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> and RESPECT<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> trials showed isolatedly this difference
(as we can see in the <xref ref-type="fig" rid="f6">Figure 6A</xref>), but the
pooled analysis did not confirm this finding. On the other hand, we might well
recognize that there is a correlation between the presence of an atrial septal
aneurysm and the risk of stroke (as we can see in the meta-regression - <xref ref-type="fig" rid="f7">Figure 7C</xref>), which led us to the conclusion
that this factor is rather a risk marker than a risk factor. Nevertheless, there
is no evidence that we should see it as a primary discriminator between those
who should have a PFO closed by means of a device.</p></sec><sec><title>The Role of the Effective Closure</title><p>The lack of efficacy observed in the CLOSURE I<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> trial has been put down to ineffective
PFO closure in the device arm, with 14% demonstrating significant residual
right-to-left shunting, whereas, in the other trials, we observed the following
rates: 7% (CLOSE<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>), 5.5% (REDUCE<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>), 6.5% (RESPECT<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>) and 6.5%
(PC<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>). Our meta-regression showed that the more successful
the closure, the lower the risk of stroke in the device group (see <xref ref-type="fig" rid="f7">Figure 7D</xref>). Therefore, we must bare in mind
that "procedural success", which was defined in the studies as successful
implantation with no complications, does not mean "success of PFO closure",
which was defined in the studies as minimal or no shunt after the procedure.</p></sec><sec><title>The Problem of Atrial Fibrillation After the Procedure</title><p>The rate of new-onset atrial fibrillation was significantly higher in the PFO
closure group than in antiplatelet group in our meta-analysis, with most cases
detected within 1 month after the procedure - a finding that suggests that the
procedure itself induces atrial fibrillation. Indeed, in the closure group, most
of the observed cases of atrial fibrillation were periprocedural. The risk of
stroke from atrial fibrillation induced by PFO closure has not been determined
in the CLOSE<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>
trial. In the REDUCE<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> trial, atrial fibrillation was more commonly
reported in the PFO closure group, but it was usually transient and the clinical
relevance of atrial fibrillation related to closure and overall risk of stroke
requires further investigation. In the CLOSURE I<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> trial, a quarter of
the strokes in the closure group were ascribed to atrial fibrillation, and in
two of these cases, the patients had deviceassociated thrombus on
transesophageal echocardiography.</p></sec><sec><title>Future Data to Come Out</title><p>At this moment, Song et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> are carrying out the DEFENSE-PFO trial (Device
Closure <italic>Versus</italic> Medical Therapy for Cryptogenic Stroke Patients
with High-Risk Patent Foramen Ovale - ClinicalTrials.gov Identifier:
NCT01550588), which will shed some additional light on this issue by assessing
whether percutaneous device closure of PFO is superior to conventional
antithrombotic treatment in preventing stroke recurrence in the cryptogenic
stroke patients with high-risk of PFO, which was defined as highrisk of
recurrence (PFO size &#x02265; 2 mm or atrial septal aneurysm or hypermobility by
transesophageal echocardiography. This study started in 2012 and will be
finished in 2020.</p></sec><sec><title>Risk of Bias and Limitations of the Present Study</title><p>There are inherent limitations with meta-analyses, including the use of
cumulative data from summary estimates. Patient data were gathered from
published data, not from individual patient follow-up. Access to individual
patient data would have enabled us to conduct further subgroup analysis and
propensity analysis to account for differences between the treatment groups.
This meta-analysis included only data from randomized studies, which do not
reflect the "real world" but, on the other hand, are less limited by publication
bias, treatment bias, confounders, and a certain tendency to overestimate
treatment effects observed in the observational studies, since patient selection
alters outcome and thus make non-randomized studies less robust.</p><p>Moreover, besides statistical heterogeneity in some analyses, there is also the
issue of the clinical heterogeneity that might have played some role in the
pooled results. For instance, in the CLOSE<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> trial, 11 different devices were
appplied for PFO closure. In the antiplatelet-only group and the PFO closure
group, 410 (86.7%) patients received aspirin, 51 (10.8%) received clopidogrel, 6
(1.3%) received aspirin with extended-release dipyridamole, and 6 (1.3%)
received aspirin with clopidogrel. As we can see, not all of patients were 100%
equally treated.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>This meta-analysis found that stroke rates are lower with percutaneously implanted
device closure than with medical therapy alone, being these rates modulated by the
rates of effective closure.</p></sec><sec><title>PERSPECTIVES</title><sec><title>What is known?</title><p>The results of the firstly published three RCTs (CLOSURE I<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>, PC<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> and
RESPECT<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>) revealed that PFO closure had a statistically
significant effect on the composite of stroke, transient ischemic attack, and
death in adjusted but not unadjusted analyses, as published in a previous pooled
analysis of individual participant data.</p></sec><sec><title>What is New?</title><p>After the publication of the two new RCTs (CLOSE<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> and
REDUCE<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>), the pooled results of our meta-analysis with the five
RCTs confirmed that PFO closure reduced the rates of stroke, but also reinforced
the problem of atrial fibrillation after the procedure, whose impact remains
unknow. This meta-analysis revealed that the more effective the closure, the
lower the risk of stroke.</p></sec><sec><title>What is Next?</title><p>The publication of the DEFENSE-PFO<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> trial will add important data to those already
available. Longer-term followup of completed trials will enhance our
understanding of the effectiveness of PFO closure, but studies of various
antithrombotic treatment regimens, including those in patients undergoing PFO
closure, are necessary to address important knowledge gaps. We still need to
know whether all of the devices are beneficial.</p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026;
responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">MPBOS</td><td align="left" valign="top" rowspan="1" colspan="1">Conception and design, analysis and
interpretation of data, drafting of the manuscript, revising it
critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LAPON</td><td align="left" valign="top" rowspan="1" colspan="1">Collection of data, drafting of the
manuscript, revising it critically for important intellectual
content; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GCSN</td><td align="left" valign="top" rowspan="1" colspan="1">Collection of data, drafting of the
manuscript, revising it critically for important intellectual
content; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EESV</td><td align="left" valign="top" rowspan="1" colspan="1">Collection of data, drafting of the
manuscript, revising it critically for important intellectual
content; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLM</td><td align="left" valign="top" rowspan="1" colspan="1">Collection of data, drafting of the
manuscript, revising it critically for important intellectual
content; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KCR</td><td align="left" valign="top" rowspan="1" colspan="1">Collection of data, drafting of the
manuscript, revising it critically for important intellectual
content; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GCN</td><td align="left" valign="top" rowspan="1" colspan="1">Collection of data, drafting of the
manuscript, revising it critically for important intellectual
content; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AMM</td><td align="left" valign="top" rowspan="1" colspan="1">Revising it critically for important
intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RFAL</td><td align="left" valign="top" rowspan="1" colspan="1">Revising it critically for important
intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FPVS</td><td align="left" valign="top" rowspan="1" colspan="1">Revising it critically for important
intellectual contente; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RCL</td><td align="left" valign="top" rowspan="1" colspan="1">Revising it critically for important
intellectual content; final approval of the version to be
published</td></tr></tbody></table></table-wrap></sec></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Division of Cardiovascular Surgery, Pronto-
Socorro Cardiol&#x000f3;gico de Pernambuco (PROCAPE), Recife, PE, Brazil.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest</p></fn></fn-group><fn-group><fn fn-type="other"><p>Fast Track Publication</p></fn><fn fn-type="COI-statement"><p>No conflict of interest</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kernan</surname><given-names>WN</given-names></name><name><surname>Ovbiagele</surname><given-names>B</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Bravata</surname><given-names>DM</given-names></name><name><surname>Chimowitz</surname><given-names>MI</given-names></name><name><surname>Ezekowitz</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Guidelines for the prevention of stroke in patients with stroke
and transient ischemic attack: a guideline for healthcare professionals from
the American Heart Association/American Stroke Association</article-title><source>Stroke</source><year>2014</year><volume>45</volume><issue>7</issue><fpage>2160</fpage><lpage>2236</lpage><pub-id pub-id-type="pmid">24788967</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><collab>PRISMA Group</collab></person-group><article-title>Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement</article-title><source>Ann Intern Med</source><year>2009</year><volume>151</volume><issue>4</issue><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">19622511</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>327</volume><issue>7414</issue><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">12958120</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Kacker</surname><given-names>R</given-names></name></person-group><article-title>Random-effects model for meta-analysis of clinical trials: an
update</article-title><source>Contemp Clin Trials</source><year>2007</year><volume>28</volume><issue>2</issue><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">16807131</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begg</surname><given-names>CB</given-names></name><name><surname>Mazumdar</surname><given-names>M</given-names></name></person-group><article-title>Operating characteristics of a rank correlation test for
publication bias</article-title><source>Biometrics</source><year>1994</year><volume>50</volume><issue>4</issue><fpage>1088</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">7786990</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Minder</surname><given-names>C</given-names></name></person-group><article-title>Bias in meta-analysis detected by a simple, graphical
test</article-title><source>BMJ</source><year>1997</year><volume>315</volume><issue>7109</issue><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">9310563</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mas</surname><given-names>JL</given-names></name><name><surname>Derumeaux</surname><given-names>G</given-names></name><name><surname>Guillon</surname><given-names>B</given-names></name><name><surname>Massardier</surname><given-names>E</given-names></name><name><surname>Hosseini</surname><given-names>H</given-names></name><name><surname>Mechtouff</surname><given-names>L</given-names></name><etal/><collab>CLOSE investigators</collab></person-group><article-title>Patent foramen ovale closure or anticoagulation vs. antiplatelets
after stroke</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><issue>11</issue><fpage>1011</fpage><lpage>1021</lpage><pub-id pub-id-type="pmid">28902593</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f8;ndergaard</surname><given-names>L</given-names></name><name><surname>Kasner</surname><given-names>SE</given-names></name><name><surname>Rhodes</surname><given-names>JF</given-names></name><name><surname>Andersen</surname><given-names>G</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Nielsen- Kudsk</surname><given-names>JE</given-names></name><etal/><collab>Gore REDUCE Clinical Study Investigators</collab></person-group><article-title>Patent foramen ovale closure or antiplatelet therapy for
cryptogenic stroke</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><issue>11</issue><fpage>1033</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">28902580</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>JD</given-names></name><name><surname>Saver</surname><given-names>JL</given-names></name><name><surname>Thaler</surname><given-names>DE</given-names></name><name><surname>Smalling</surname><given-names>RW</given-names></name><name><surname>Berry</surname><given-names>S</given-names></name><name><surname>MacDonald</surname><given-names>LA</given-names></name><etal/><collab>RESPECT Investigators</collab></person-group><article-title>Closure of patent foramen ovale versus medical therapy after
cryptogenic stroke</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><issue>12</issue><fpage>1092</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">23514286</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>B</given-names></name><name><surname>Kalesan</surname><given-names>B</given-names></name><name><surname>Mattle</surname><given-names>HP</given-names></name><name><surname>Khattab</surname><given-names>AA</given-names></name><name><surname>Hildick-Smith</surname><given-names>D</given-names></name><name><surname>Dudek</surname><given-names>D</given-names></name><etal/><collab>PC Trial Investigators</collab></person-group><article-title>Percutaneous closure of patent foramen ovale in cryptogenic
embolism</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><issue>12</issue><fpage>1083</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">23514285</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furlan</surname><given-names>AJ</given-names></name><name><surname>Reisman</surname><given-names>M</given-names></name><name><surname>Massaro</surname><given-names>J</given-names></name><name><surname>Mauri</surname><given-names>L</given-names></name><name><surname>Adams</surname><given-names>H</given-names></name><name><surname>Albers</surname><given-names>GW</given-names></name><etal/><collab>CLOSURE I Investigators</collab></person-group><article-title>Closure or medical therapy for cryptogenic stroke with patent
foramen ovale</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>11</issue><fpage>991</fpage><lpage>999</lpage><pub-id pub-id-type="pmid">22417252</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Tullio</surname><given-names>MR</given-names></name><name><surname>Sacco</surname><given-names>RL</given-names></name><name><surname>Sciacca</surname><given-names>RR</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name></person-group><article-title>Patent foramen ovale and the risk of ischemic stroke in a
multiethnic population</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>49</volume><issue>7</issue><fpage>797</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">17306710</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Sacco</surname><given-names>RL</given-names></name><name><surname>Di Tullio</surname><given-names>MR</given-names></name><name><surname>Sciacca</surname><given-names>RR</given-names></name><name><surname>Mohr</surname><given-names>JP</given-names></name><collab>PFO in Cryptogenic Stroke Study (PICSS) Investigators</collab></person-group><article-title>Effect of medical treatment, in stroke patients with patent
foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke
Study</article-title><source>Circulation</source><year>2002</year><volume>105</volume><issue>22</issue><fpage>2625</fpage><lpage>2631</lpage><pub-id pub-id-type="pmid">12045168</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>DM</given-names></name><name><surname>Dahabreh</surname><given-names>IJ</given-names></name><name><surname>Ruthazer</surname><given-names>R</given-names></name><name><surname>Furlan</surname><given-names>AJ</given-names></name><name><surname>Reisman</surname><given-names>M</given-names></name><name><surname>Carroll</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Device closure of patent foramen ovale after stroke: pooled
analysis of completed randomized trials</article-title><source>J Am Coll Cardiol</source><year>2016</year><volume>67</volume><issue>8</issue><fpage>907</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">26916479</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Klemperer</surname><given-names>K</given-names></name><name><surname>Kempny</surname><given-names>A</given-names></name><name><surname>Pavitt</surname><given-names>CW</given-names></name><name><surname>Janssen</surname><given-names>JC</given-names></name><name><surname>Uebing</surname><given-names>A</given-names></name><name><surname>Nicol</surname><given-names>E</given-names></name></person-group><article-title>Device closure for patent foramen ovale following cryptogenic
stroke: a survey of current practice in the UK</article-title><source>Open Heart</source><year>2017</year><volume>4</volume><issue>2</issue><elocation-id>e000636</elocation-id><pub-id pub-id-type="pmid">29081978</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Song</surname><given-names>JK</given-names></name><name><surname>Busan</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Jeong</surname><given-names>SS</given-names></name><name><surname>Shin</surname><given-names>ES</given-names></name></person-group><source>Device closure versus medical therapy for cryptogenic stroke patients
with high-risk patent foramen ovale (DEFENSE-PFO)</source><date-in-citation content-type="access-date">2017 Dec 15</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT01550588">https://clinicaltrials.gov/ct2/show/study/NCT01550588</ext-link></comment></element-citation></ref></ref-list></back></article>